STAT3 interactome predicts presence of proteins that regulate immune system in oral squamous cell carcinoma

Rajdeep Chakraborty1, Pallavi Khodlan2, Aidan Tay3

  • 1Applied Biosciences, Faculty of Science and Engineering, Macquarie University, Sydney, NSW, 2109, Australia; School of Natural Sciences, Faculty of Science and Engineering, Macquarie University, Sydney, NSW, 2109, Australia.

Journal of Oral Biosciences
|September 5, 2024
PubMed
Abstract

Insights

Signal transducer and activator of transcription 3 (STAT3) interacts with proteins that drive oral squamous cell carcinoma (OSCC) progression. These STAT3-binding partners are key regulators of the immune system in OSCC.

Area of Science:

  • Oncology
  • Immunology
  • Molecular Biology

Background:

  • Signal transducer and activator of transcription 3 (STAT3) is crucial for oral squamous cell carcinoma (OSCC) progression.
  • STAT3 facilitates immune evasion in OSCC via the JAK2/STAT3/PDL1 signaling axis.

Purpose of the Study:

  • To investigate STAT3-binding partners involved in inhibiting anti-tumor activity in OSCC.
  • To elucidate the role of STAT3 interactome in OSCC immune evasion.

Main Methods:

  • A 3D cancer-immune co-culture model using OSCC cell lines (SCC4, SCC9, SCC25, CAL27) and normal oral cells (OKF6) with immune cells (NK-92, Jurkat).
  • Co-immunoprecipitation (Co-IP)-based proteomics targeting STAT3, followed by LC-MS/MS analysis.
  • Bioinformatic analysis including protein interaction network, gene ontology, and pathway analysis.

Main Results:

  • STAT3 was found to interact with epidermal growth factor receptor (EGFR) and other proteins involved in proliferation and immune regulation in OSCC cell lines.
  • Proteomic analysis identified STAT3-binding proteins that are known regulators of the immune system.

Conclusions:

  • STAT3 interactive proteins play a significant role in regulating the immune system within oral squamous cell carcinoma.
  • Understanding these interactions may reveal novel therapeutic targets for OSCC.